Is there a difference in the ‘hunger’ hormone between Pacific Island and New Zealand European populations?

Not Applicable

Not yet recruiting

• Conditions: Health; Diabetes Mellitus (DM); Metabolic and Endocrine - Diabetes; Cardiovascular - Normal development and function of the cardiovascular system

• Registration Number: ACTRN12624001158550
• Lead Sponsor: University of Auckland

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2024-09-24
• Last Update Posted: 30 September 2024

Recruitment & Eligibility

• Status: Not yet recruiting
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

All cohorts: Men and women aged 18 years or older; Cohort 1: Healthy Pacific Island (both biological parents of Pacific Island origin) participants Healthy NZ European (both biological parents of New Zealand origin) participants Healthy Pacific Island (both biological parents of Pacific Island origin) living in NZ or Samoa; Cohort 2: Healthy NZ European participants; Cohort 3: T2D Pacific Island (both biological parents of Pacific Island origin) participants T2D NZ European (both biological parents of New Zealand origin) participants •Pacific Island (both biological parents of Pacific Island origin) and non-Pacific (NZ European) participants •Healthy participants •Type 2 diabetics

Exclusion Criteria

•Severe cardiac disease (e.g., coronary artery disease, heart failure)•Significant arrhythmias (e.g., atrial fibrillation, previous VT / significant ventricular ectopy)•Severe respiratory disease (e.g., chronic obstructive pulmonary disease)•Significant renal or liver disease•Significant neurological disease including diabetic neuropathy•Significant obesity (i.e., not having a body fat% >30% for men and >42% for women)•Current active treatment for cancer•Inflammatory disease•Current infection or pyrexial illness•Uncontrolled thyroid disorders•Recent (< 3 months) ischemic stroke•Current pregnancy•Inability to fully or appropriately provide consent (e.g., language issue, reading capability)•Underlying medical conditions, which in the opinion of the Investigator place the participant at unacceptably high risk for participating in the study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Plasma levels of ghrelin in healthy Pacific Island (PI), compared to healthy New Zealanders (NZ) Europeans.[Plasma ghrelin concentration will be assessed by blood sample.<br> Plasma levels of ghrelin will be assessed once at the experimental visit in healthy PI and healthy NZ Europeans participants.<br>];Muscle sympathetic nerve activity (MSNA) in healthy Pacific Island (PI), compared to healthy New Zealanders (NZ) Europeans[MSNA will be assessed by microneurography. MSNA in healthy PI and NZ Europeans participants will be assessed at four timepoints during the experimental visit: at rest, during slow deep breathing, during Valsalva manoeuvre and during hyperoxia.]

Secondary Outcome Measures

Name	Time	Method
The levels of ghrelin in type 2-diabetic (T2D) PI populations compared to T2D NZ European population.[Plasma ghrelin concentration will be assessed by blood sample. Plasma levels of ghrelin will be assessed once at the experimental visit in T2D PI and T2D NZ Europeans participants.];MSNA in T2D PI compared to T2D NZ European. [Muscle sympathetic nerve activity will be assessed by microneurography. MSNA in T2D PI and NZ Europeans participants will be assessed at four timepoints during the experimental visit: at rest, during slow deep breathing, during Valsalva manoeuvre and during hyperoxia.]